These two medicines are effective in fighting Omicron, WHO gave new instructions

Corona cases in the country are breaking their records every day. The third wave of Corona has wreaked such havoc on the country and the world, that there is panic all around. Along with India, Corona is wreaking havoc in America and European countries. Till now only vaccine is the only effective medicine to recover from the corona. But the trouble is that now after the arrival of the new Omicron variant, the corona is also catching people who have taken both the corona vaccines.

WHO told these two medicines

The increasing effects of corona and the people getting infected have told the World Health Organization i.e. WHO a new medicine for corona. Which can prove to be a boon for corona patients. WHO – baricitinib and Basiliximab-Imdevimab. Experts from the health body in the peer-reviewed journal BMJ said that baricitinib can be used with corticosteroids to treat critically ill patients. This medicine is commonly used in the treatment of arthritis.

Take medicine only based on clinical experience

WHO has claimed that the use of this drug can reduce the usefulness of ventilators. The special thing is that there is no side effect of this medicine, due to which there is no danger to the life of the patient. The WHO said that the use of this drug is similar to interleukin-6, another medicine for arthritis. If both the medicines are available to you then based on the clinical experience you can buy this medicine. Also, the WHO specifically said that both medicines should not be taken together.

Another antibody is also recommended

The WHO has updated the guidelines to recommend the use of the monoclonal antibody sotrovimab taking into account the circumstances. This drug can be given to such a patient who can be given to patients with a low risk of infection but hospitalization. The WHO has also made a similar recommendation for another monoclonal antibody drug, Basiliximab-Imdevimab.

Guidelines will be updated after getting enough data

However, a statement issued by the WHO also said that there was not enough data available to recommend monoclonal antibody treatment and the health body also acknowledged that its effectiveness against new variants such as Omicron is not currently known. The guideline will be updated if sufficient data of monoclonal antibodies are found.

Evidence found in trials on infected patients

These recommendations of WHO is based on evidence found in seven trials on 4,000 common, less severe and more severe infected patients. All these patients are part of a living guideline developed by WHO in collaboration with the Methodological Support of Magic Evidence Ecosystem Foundation. So that reliable guidelines can be given for Covid-19 management and doctors treating patients can also take better decisions.